Cover Image
市場調查報告書

帶狀皰疹後遺症神經痛:開發平台分析

Postherpetic Neuralgia - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 192785
出版日期 內容資訊 英文 98 Pages
訂單完成後即時交付
價格
Back to Top
帶狀皰疹後遺症神經痛:開發平台分析 Postherpetic Neuralgia - Pipeline Review, H2 2016
出版日期: 2016年09月28日 內容資訊: 英文 98 Pages
簡介

帶狀皰疹後神經痛是帶狀皰疹(皰疹)的併發症,是水痘(帶狀皰疹)病毒所引起的。主要的症狀有疼痛、輕微接觸也會有發癢·發麻的敏感感覺、倦怠感、麻痺狀態等。致病的危險因子有年齡、HIV病毒·何杰金氏淋巴瘤的感染病史等。主要的治療藥有抗痙攣藥和抗憂鬱劑,Opioids(類鴉片物質)止痛藥等。

本報告提供全球各國治療帶狀皰疹後遺症神經痛(PHN)所用之開發中產品的開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

帶狀皰疹後遺症神經痛概要

治療藥的開發

  • 帶狀皰疹後遺症神經痛開發中產品:概要
  • 帶狀皰疹後遺症神經痛開發中產品:比較分析

各企業開發中的帶狀皰疹後遺症神經痛治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 不明確階段的產品

帶狀皰疹後遺症神經痛治療藥:開發中的產品一覽(各企業)

帶狀皰疹後遺症神經痛開發治療藥的企業

  • Aestus Therapeutics, Inc.
  • Allergan Plc
  • Astellas Pharma Inc.
  • Daewoong Pharmaceutical Co., Ltd.
  • 第一三共
  • Immune Pharmaceuticals Inc.
  • Merck & Co., Inc.
  • Nuvo Research Inc.
  • Pfizer Inc.
  • Phosphagenics Limited
  • Purdue Pharma L.P.
  • Relmada Therapeutics, Inc.
  • Scilex Pharmaceuticals, Inc.
  • Teva Pharmaceutical Industries Limited
  • Winston Pharmaceuticals, Inc.

帶狀皰疹後遺症神經痛:治療藥的評估

  • 單劑治療藥的情況
  • 並用治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • (amitriptyline + ketamine hydrochloride)
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • (naltrexone hydrochloride+ clonidine hydrochloride)
  • ASP-8477
  • ATX-08001
  • bupivacaine hydrochloride
  • C-746
  • CNV-2197944
  • DWP-05195
  • Flexicaine
  • funapide
  • FV-100
  • ketoprofen
  • lidocaine hydrochloride
  • lidocaine hydrochloride patch
  • mepivacaine hydrochloride
  • mirogabalin besylate
  • MK-8291
  • NXN-462
  • oxycodone ER
  • pregabalin CR
  • senrebotase
  • V-116517
  • zucapsaicin

帶狀皰疹後遺症神經痛治療藥:開發中產品的最新趨勢

帶狀皰疹後遺症神經痛治療藥:開發暫停的產品

帶狀皰疹後遺症神經痛治療藥:開發中止的產品

帶狀皰疹後遺症神經痛相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8487IDB

Summary

Global Markets Direct's, 'Postherpetic Neuralgia - Pipeline Review, H2 2016', provides an overview of the Postherpetic Neuralgia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Postherpetic Neuralgia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Postherpetic Neuralgia and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Postherpetic Neuralgia
  • The report reviews pipeline therapeutics for Postherpetic Neuralgia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Postherpetic Neuralgia therapeutics and enlists all their major and minor projects
  • The report assesses Postherpetic Neuralgia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Postherpetic Neuralgia

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Postherpetic Neuralgia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Postherpetic Neuralgia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Postherpetic Neuralgia Overview
  • Therapeutics Development
    • Pipeline Products for Postherpetic Neuralgia - Overview
  • Postherpetic Neuralgia - Therapeutics under Development by Companies
  • Postherpetic Neuralgia - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Postherpetic Neuralgia - Products under Development by Companies
  • Postherpetic Neuralgia - Companies Involved in Therapeutics Development
    • Aestus Therapeutics, Inc.
    • ContraVir Pharmaceuticals, Inc.
    • Daewoong Pharmaceutical Co., Ltd.
    • Daiichi Sankyo Company, Limited
    • Immune Pharmaceuticals Inc.
    • Jiangsu Hengrui Medicine Co., Ltd.
    • KPI Therapeutics, Inc.
    • Lpath, Inc.
    • Merck & Co., Inc.
    • Patagonia Pharmaceuticals, LLC
    • Pfizer Inc.
    • Phosphagenics Limited
    • Relmada Therapeutics, Inc.
    • Scilex Pharmaceuticals, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Toray Industries, Inc.
  • Postherpetic Neuralgia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (amitriptyline + ketamine hydrochloride) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (clonidine hydrochloride + naltrexone hydrochloride) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ATX-08001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bupivacaine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • C-746 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DWP-05195 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • funapide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FV-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ketoprofen - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lidocaine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lidocaine hydrochloride patch - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Lpathomab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mepivacaine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mirogabalin besylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MK-8291 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • naltrexone hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PATN-02 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pregabalin CR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pregabalin SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • REL-1017 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TRK-700 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • U-2902 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • zucapsaicin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Postherpetic Neuralgia - Dormant Projects
  • Postherpetic Neuralgia - Discontinued Products
  • Postherpetic Neuralgia - Product Development Milestones
    • Featured News & Press Releases
      • Jun 16, 2016: ContraVir Pharmaceuticals Expands Patient Enrollment Criteria for Ongoing Phase 3 Clinical Study of FV-100 for Treating Shingles
      • May 12, 2016: SCILEX Pharmaceuticals Study Suggests Underutilization of Recommended First-Line Lidocaine Patches and Opioid Overuse for Treatment of Pain Associated with Post-Herpetic Neuralgias
      • Apr 22, 2016: SCILEX Pharmaceuticals Reports First-Line Treatments Including Lidocaine Patches for Post-Herpetic Neuralgia Are Significantly Underutilized
      • Mar 03, 2016: ContraVir Pharmaceuticals Reports Positive Results Confirming the Safety of its Shingles Candidate FV-100 in a Drug-Drug Interaction Study
      • Dec 10, 2015: SCILEX Pharmaceuticals Announces Executive Hires
      • Sep 16, 2015: FDA Accepts SCILEX Pharmaceuticals' NDA Filing for ZTlido
      • Jun 09, 2015: ContraVir Pharmaceuticals Selects ImageIQ as Imaging CRO for Phase III Clinical Trial
      • Apr 02, 2015: Teva and Xenon Announce Enrollment of First Patient in a Phase 2b Study Evaluating TV-45070 for Postherpetic Neuralgia
      • Feb 20, 2015: ContraVir Pharmaceuticals Provides Clinical Update on FV-100
      • Feb 19, 2015: Xenon Pharmaceuticals Partner Teva to Initiate Phase 2b Clinical Trial of TV-45070 in Post-Herpetic Neuralgia
      • Feb 04, 2015: Daiichi Sankyo Announces First Patients in Large-scale, Multi-national Phase 3 Clinical Programs for Mirogabalin
      • Jan 07, 2015: ContraVir Pharmaceuticals Granted FDA Meeting to Discuss Proposal for Phase 3 Trial of FV-100
      • Dec 18, 2014: Pfizer Reports Top-Line Results From a Phase 3 Study Evaluating Pregabalin Controlled-Release Formulation as a Treatment for Patients With Postherpetic Neuralgia
      • Aug 11, 2014: Scilex Pharmaceuticals Completes Trial Enrollment for Ztlido
      • Jul 14, 2014: SCILEX Pharmaceuticals Commences Dermal Safety Studies of Ztlido
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Postherpetic Neuralgia, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Postherpetic Neuralgia - Pipeline by Aestus Therapeutics, Inc., H2 2016
  • Postherpetic Neuralgia - Pipeline by ContraVir Pharmaceuticals, Inc., H2 2016
  • Postherpetic Neuralgia - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016
  • Postherpetic Neuralgia - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
  • Postherpetic Neuralgia - Pipeline by Immune Pharmaceuticals Inc., H2 2016
  • Postherpetic Neuralgia - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016
  • Postherpetic Neuralgia - Pipeline by KPI Therapeutics, Inc., H2 2016
  • Postherpetic Neuralgia - Pipeline by Lpath, Inc., H2 2016
  • Postherpetic Neuralgia - Pipeline by Merck & Co., Inc., H2 2016
  • Postherpetic Neuralgia - Pipeline by Patagonia Pharmaceuticals, LLC, H2 2016
  • Postherpetic Neuralgia - Pipeline by Pfizer Inc., H2 2016
  • Postherpetic Neuralgia - Pipeline by Phosphagenics Limited, H2 2016
  • Postherpetic Neuralgia - Pipeline by Relmada Therapeutics, Inc., H2 2016
  • Postherpetic Neuralgia - Pipeline by Scilex Pharmaceuticals, Inc., H2 2016
  • Postherpetic Neuralgia - Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016
  • Postherpetic Neuralgia - Pipeline by Toray Industries, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Postherpetic Neuralgia - Dormant Projects, H2 2016
  • Postherpetic Neuralgia - Dormant Projects (Contd..1), H2 2016
  • Postherpetic Neuralgia - Dormant Projects (Contd..2), H2 2016
  • Postherpetic Neuralgia - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Postherpetic Neuralgia, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top